Carcinolipin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412332

CAS#: 19477-24-8

Description: Carcinolipin is a biochemical with endogenous carcinogenic effects


Chemical Structure

img
Carcinolipin
CAS# 19477-24-8

Theoretical Analysis

MedKoo Cat#: 412332
Name: Carcinolipin
CAS#: 19477-24-8
Chemical Formula: C44H78O2
Exact Mass: 638.6002
Molecular Weight: 639.11
Elemental Analysis: C, 82.69; H, 12.30; O, 5.01

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Carcinolipin; BRN2493354; BRN-2493354; BRN 2493354

IUPAC/Chemical Name: Cholest-5-en-3-beta-ol, 14-methylhexadecanoate

InChi Key: ILZPADCYIWUDSX-JZMMRQARSA-N

InChi Code: InChI=1S/C44H78O2/c1-8-34(4)21-17-15-13-11-9-10-12-14-16-18-23-42(45)46-37-28-30-43(6)36(32-37)24-25-38-40-27-26-39(35(5)22-19-20-33(2)3)44(40,7)31-29-41(38)43/h24,33-35,37-41H,8-23,25-32H2,1-7H3/t34?,35-,37+,38+,39-,40+,41+,43+,44-/m1/s1

SMILES Code: CC(C)CCC[C@@H](C)[C@H]1CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](OC(CCCCCCCCCCCCC(C)CC)=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 639.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hradec J, Dolejs L. The chemical constitution of carcinolipin. Biochem J. 1968 Mar;107(2):129-34. doi: 10.1042/bj1070129. PMID: 5689245; PMCID: PMC1198637.

2: Hradec J. Effect of carcinolipin on the adenosine triphosphatase activity of isolated cellular fractions. Nature. 1965 Aug 28;207(5000):982-3. doi: 10.1038/207982b0. PMID: 4223269.

3: Hradec J. A chromatographic method for the quantitative determination of cholesterol 14-methylhexadecanoate (carcinolipin) in biological materials. J Chromatogr. 1968 Feb 6;32(3):511-8. doi: 10.1016/s0021-9673(01)80523-9. PMID: 4295862.

4: FRIBORSKY V. LIVER CHANGES CAUSED BY CARCINOLIPIN. Neoplasma. 1964;11:55-61. PMID: 14116775.

5: Hradec J, Mensík P. Purification of the fatty acid present in carcinolipin. J Chromatogr. 1968 Feb 6;32(3):502-10. doi: 10.1016/s0021-9673(01)80522-7. PMID: 5689452.

6: HRADEC J, KRUML J. Carcinolipin: an endogenous carcinogenic substance. Nature. 1960 Jan 2;185:55. doi: 10.1038/185055a0. PMID: 14403538.

7: Kolesnichenko TS, Savluchinskaia LA. O transplatsentarnom deĭstvii kartsinolipina [Transplacental action of carcinolipin]. Vopr Onkol. 1975;21(3):101-3. Russian. PMID: 1130012.

8: HRADEC J. CARCINOLIPIN--AN ESSENTIAL FACTOR IN PROTEIN SYNTHESIS. Acta Unio Int Contra Cancrum. 1964;20:926-8. PMID: 14274754.

9: Shabad LM, Kolesnichenko TS, Savluchinskaya LA. Transplacental effect of carcinolipin in mice. Neoplasma. 1973;20(3):347-8. PMID: 4725520.

10: HRADEC J. Effect of carcinolipin on protein synthesis in cell-free systems. Biochim Biophys Acta. 1961 Feb 12;47:149-57. doi: 10.1016/0006-3002(61)90840-x. PMID: 13716315.